Approved by the FDA in June 2001, the BioEnterics® LAP-BAND Adjustable Gastric Banding System is the least invasive and the only adjustable surgical treatment for morbid obesity in the United States. It induces weight loss by reducing the capacity of the stomach, which restricts the amount of food that can be consumed. Since its clinical introduction in 1993, more than 120,000 LAP-BAND procedures have been performed around the world.

Minimally Invasive

• Least invasive surgical option
• No intestinal re-routing
• No cutting or stapling of the stomach wall or bowel
• Reduced patient pain, hospital length-of-stay and recovery period

Fewer Risks and Side Effects

• Significantly lower mortality risk than other obesity surgeries1
• Low risk of nutritional deficiencies associated with gastric bypass
• Reduced risk of hair loss
• No “dumping syndrome” related to dietary intake restrictions

Adjustable

• Allows individualized degree of restriction for ideal, long-term weight loss
• Adjustments performed without additional surgery
• Supports pregnancy by allowing adjustment for increased nutritional needs

Reversible

• Removable at any time
• A Stomach and other anatomy are generally restored to their original forms and functions

Effective Long-Term Weight Loss

• More than 120,000 cases performed worldwide
• Standard of care for hundreds of practices around the world
• Academic publications with up to 8 years of follow-up

Executive summary: Laparoscopic adjustable gastric banding for the treatment of obesity (Update and Re-appraisal). The Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIPS) 2002; 1. (Laparoscopic adjustable gastric banding surgery, like the LAP-BAND surgery, is associate with a mean short-term mortality rate of around 0.05% compared to 0.50% for Gastric Bypass and 0.31% for Vertical Banded Gastroplasty.)